Alnylam Pharmaceuticals, Inc. - Net Worth and Insider Trading
Alnylam Pharmaceuticals, Inc. Net Worth
The estimated net worth of Alnylam Pharmaceuticals, Inc. is at least $61,209 dollars as of 2024-11-13. Alnylam Pharmaceuticals, Inc. is the 10% Owner of Regulus Therapeutics Inc and owns about 40,806 shares of Regulus Therapeutics Inc (RGLS) stock worth over $61,209. Details can be seen in Alnylam Pharmaceuticals, Inc.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Alnylam Pharmaceuticals, Inc. has not made any transactions after 2016-02-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Alnylam Pharmaceuticals, Inc. owns 1 companies in total, including Regulus Therapeutics Inc (RGLS) .
Click here to see the complete history of Alnylam Pharmaceuticals, Inc.’s form 4 insider trades.
Insider Ownership Summary of Alnylam Pharmaceuticals, Inc.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RGLS | Regulus Therapeutics Inc | 2016-02-23 | 10 percent owner |
Alnylam Pharmaceuticals, Inc. Latest Holdings Summary
Alnylam Pharmaceuticals, Inc. currently owns a total of 1 stock. Alnylam Pharmaceuticals, Inc. owns 40,806 shares of Regulus Therapeutics Inc (RGLS) as of February 23, 2016, with a value of $61,209.
Latest Holdings of Alnylam Pharmaceuticals, Inc.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RGLS | Regulus Therapeutics Inc | 2016-02-23 | 40,806 | 1.50 | 61,209 |
Holding Weightings of Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Form 4 Trading Tracker
According to the SEC Form 4 filings, Alnylam Pharmaceuticals, Inc. has made a total of 0 transactions in Regulus Therapeutics Inc (RGLS) over the past 5 years. The most-recent trade in Regulus Therapeutics Inc is the sale of 8,333 shares on February 23, 2016, which brought Alnylam Pharmaceuticals, Inc. around $7 Million.
Insider Trading History of Alnylam Pharmaceuticals, Inc.
- 1
Alnylam Pharmaceuticals, Inc. Trading Performance
Alnylam Pharmaceuticals, Inc. Ownership Network
Ownership Network List of Alnylam Pharmaceuticals, Inc.
Ownership Network Relation of Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Owned Company Details
What does Regulus Therapeutics Inc do?
Who are the key executives at Regulus Therapeutics Inc?
Alnylam Pharmaceuticals, Inc. is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Financial Officer Crispina Calsada , Sr. VP & General Counsel Christopher Ray Aker , and Chief Operating Officer Joseph P Hagan .
Regulus Therapeutics Inc (RGLS) Insider Trades Summary
Over the past 18 months, Alnylam Pharmaceuticals, Inc. made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Christopher Ray Aker , and a net sale of 5,468 shares made by Crispina Calsada .
In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.
Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regulus Therapeutics Inc Insider Transactions
Alnylam Pharmaceuticals, Inc. Mailing Address
Above is the net worth, insider trading, and ownership report for Alnylam Pharmaceuticals, Inc.. You might contact Alnylam Pharmaceuticals, Inc. via mailing address: 675 West Kendall Street, Henri A. Termeer Square, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
